Fast-food chain McDonald’s, an economic indicator because of its mammoth global presence, posted its worst earnings report since 2020.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
A report from the London School of Economics shows climate litigation is on the rise, although the cases filed each year may be stabilizing.
AI’s energy needs are enormous, and could have a once-in-a-generation impact on the electricity market.
Walgreens’ new leader is planning a rebound for the chain, starting with shuttering a substantial, if unspecified, number of US locations.
Novo Nordisk, maker of weight-loss drug Wegovy, struck a deal with online telehealth storefronts that sold cheap knockoffs during shortages.
A quarterly survey by the Federal Reserve Bank of Dallas polls around 140 energy firm executives in Texas, Louisiana, and New Mexico.
The Department of Health announced this week that Medicare is cutting prices for dozens of prescription drugs that have outpaced inflation.
Independent film and TV house A24 scored a $100 million investment at a valuation of $3.5 billion in its second fundraise in as many years.
Reducing beverage-wait times is part of Starbucks CEO Brian Niccol’s turnaround plan, which includes tech updates focused on efficiency.
Novo Nordisk scored approval to sell its Wegovy weight loss drug in China. That’s a big win, but competitors will soon flood in.
As the frequency of cyberattacks on healthcare systems and hospitals increases, so too do the costs for preventing them.
Chipotle is the only food chain among the top 20 best-performing stocks on the S&P 500 this year. So what’s the secret to its success?
To prepare for a slowdown of global trade, US retailers spent months building a massive inventory to prevent empty shelves.
Hertz’s recent track record leaves much to be desired: the rental-car company lost nearly $2.9 billion last year.
Investor worries about a fresh batch of US tariffs have dragged LVMH shares in Paris down 23.6% so far this year.
The company plans to seek regulatory approval for the revolutionary weight loss treatment by the end of the year.